

INVITATION

23 May 2025

9th NORDIC PHOTOPHERESIS MEETING

Scandic Spectrum, Copenhagen, Denmark

This information is intended for healthcare professionals based in Europe and the Middle East

Agenda

Time: 08:30 – 16:00


08:00 – 08:30	Registration & Coffee	
SESSION 1		
Moderator	Prof. James Hutchinson, University Hospital Regensburg, Germany	
08:30 – 08:35	Welcome & introduction Prof. James Hutchinson, University Hospital Regensburg, Germany	
08:35 – 09:15	New mechanistic insights and utility in GvHD and solid organ transplantation Prof. James Hutchinson, University Hospital Regensburg, Germany	
09:15 – 09:30	EClad – Randomised controlled trial of ECP in the treatment of CLAD Prof. Andrew Fisher, Newcastle University, United Kingdom	
09:30 – 09:40	Q&A session 1	
09:40 – 09:50	Coffee / Move to Breakout room	
SESSION 2		
GvHD		Lung
Moderator	Dr. Marietta Nygaard, Rigshospitalet, Denmark	Moderator Prof. Michael Perch, Rigshospitalet, Denmark
09:50 – 10:20	Novel approaches to GvHD prophylaxis Dr. Varun Mehra, Kings College Hospital, London	09:50 – 10:10ECP technical overview Jesper Nilsson, Sr Clinical Specialist, Therakos
10:20 – 10:50	Potential Novel Biomarkers in GvHD Prof. Robert Zeiser, University Hospital Freiburg, Germany	10:10 – 10:40Extracorporeal photopheresis in lung transplantation – how to prevent and treat LuTx complications Dr. Jesper Magnusson, Sahlgrenska Universitetssjukhuset, Sweden
10:50 – 11:20	Current and emerging treatment approaches for acute & chronic GvHD Prof. Hildegard Greinix, Medical University of Vienna, Austria	10:40 – 11:10Randomized controlled trial on the use of ECP as a preventional approach after lung transplantation Prof. Peter Jaksch, Vienna Medical Hospital, Austria
11:20 – 11:30	Q&A session 2	11:10 – 11:40Usage of ECP after LuTX and development of infections Dr. Martin Carby, Harefield Hospital, United Kingdom
11:30 – 12:00	A patient story - Complications of late diagnosis Jenny Bandheim	11:40 – 12:00Q&A session 2
12:00 – 13:00	Lunch	
SESSION 3		
GvHD		Lung
Moderator	Dr. Marietta Nygaard, Rigshospitalet, Denmark	Moderator Prof. Michael Perch, Rigshospitalet, Denmark
13:00 – 13:30	Use of ECP for GvHD in different organs Prof. Hildegard Greinix, Medical University of Vienna, Austria	13:00 – 13:30Vienna experience on ECP use in the treatment pathway of ABMR after LuTX Prof. Peter Jaksch, Vienna Medical Hospital, Austria
13:30 – 14:00	ECP and combination therapy Prof. Robert Zeiser, University Hospital Freiburg, Germany	13:30 – 14:00Update on a prospective ECP: Registry after Lung Transplant (PORPOise) at Rigshospitalet Denmark Prof. Michael Perch, Rigshospitalet, Denmark
14:00 – 14:10	Q&A session 3	14:00 – 14:10Q&A session 3
14:10 – 14:20	Coffee / Move to Breakout room	
SESSION 4		
Moderator	Prof. James Hutchinson, University Hospital Regensburg, Germany	
14:20 – 14:50	Pulmonary graft-versus-host disease and chronic lung allograft dysfunction: two sides of the same coin? Dr. Saskia Bos, University Hospital Leuven, Belgium	
14:50 – 15:05	CLAD patient case – How would you manage this? Dr. Jesper Magnusson, Sahlgrenska Universitetssjukhuset, Sweden	
15:05 – 15:20	Lung GvHD patient case – How would you manage this? Dr. Pål Tore Bentsen, Haukeland Sykehus, Norway	
15:20 – 15:50	Panel Discussion – Discussion on patient cases from an immunologist point of view Prof. James Hutchinson, University Hospital Regensburg, Germany	
15:50 – 16:00	Closing Dr. Marietta Nygaard and Prof. Michael Perch, Rigshospitalet, Denmark	

ECP: Extracorporeal Photopheresis, aGvHD: Acute Graft versus Host Disease, GvHD: Graft versus Host Disease, cGvHD: Chronic Graft versus Host Disease

All speakers are subject to contract.

This is a commercial programme run by Therakos (UK) Ltd.

Follow the
Therakos Institute



[Privacy policy](#)

For more information on THERAKOS ECP Immunomodulation™ please visit www.therakos.eu

Therakos, the circle brand mark and the Therakos logo are trademarks of a Therakos company.
Other brands are trademarks of a Therakos company or their respective owners. © 2025 Therakos.

Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our privacy policy provides additional information.

EU-2500013 05/2025.